Non-gastric extra-nodal marginal zone lymphomas--a single centre experience on 76 patients
| Autor: | Eleni Papadaki, Panagiota Roussou, Tatiana Tzenou, Theodoros P. Vassilakopoulos, Xanthi Yiakoumis, Maria K. Angelopoulou, Sotirios Sahanas, Flora N. Kontopidou, Marina P. Siakantaris, Christina Kalpadakis, Dimitra Anagnostou, Evangelos Patsouris, Panayiotis Panayiotidis, Evangelia M. Dimitriadou, Gerassimos A. Pangalis, Panagia Bobotsis, Penelope Korkolopoulou, Maria-Christina Kyrtsonis |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
Adult
Male Cancer Research medicine.medical_specialty Antineoplastic Agents Gastroenterology Young Adult Internal medicine medicine Humans Progression-free survival Lymph node Survival analysis Aged Retrospective Studies Aged 80 and over Lung Chlorambucil business.industry Remission Induction Hematology Lymphoma B-Cell Marginal Zone Middle Aged medicine.disease Marginal zone Survival Analysis Lymphoma Surgery medicine.anatomical_structure Treatment Outcome Oncology Female Bone marrow business medicine.drug |
| Zdroj: | Leukemialymphoma. 49(12) |
| ISSN: | 1029-2403 |
| Popis: | In the present study, we assessed the clinical and pathological data of 76 patients with the diagnosis of non-gastric extranodal marginal zone B-cell lymphoma. The most commonly affected sites were salivary glands, skin, ocular adnexa, lung, intestine and Waldeyer's ring. Ann Arbor stage I disease was present in 39 patients (51%), stage II in 10 (13%) and stage IV in 27 (36%). In 17 cases (21%), the lymphoma presented at multiple mucosal sites. Lymph node and bone marrow involvement were present in 21% and 16%, respectively. Most cases were in the low or low-intermediate risk group. Treatment was heterogeneous and included chlorambucil in 59% either alone or in combination with other agents. Complete and partial remission was achieved in 79% and 7%, respectively, with an overall response rate of 86%. The 5- and 10-year overall survival and cause-specific survival rates were 94%, 82% and 95%, 91%, respectively. The 5- and 10-year progression free survival was 56% and 41%, respectively. The only feature associated with inferior outcome was disease localisation to the lung. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
| Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |